Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-23T08:18:05.167Z Has data issue: false hasContentIssue false
  • English
  • Français

A Trial of Fluphenazine in Schizophrenia

Published online by Cambridge University Press:  29 January 2018

John Millar
John Millar*
Affiliation:
Carlton Hayes Hospital, Narborough, near Leicester
Get access Rights & Permissions [Opens in a new window]

Extract

Fluphenazine, one of the newest phenothiazine derivatives, has trifluoromethyl and piperazine groups which bring about increase in potency. In Britain it is used in doses of 1 mg. or 2 mg. daily for the relief of anxiety, but American reports indicate that the drug is also of value in psychotic illnesses (Darling, 1959; Niswander and Karacan, 1959; Taylor, 1959, 1960; Darling et al., 1960; Holt and Wright, 1960). Encouraging results were also obtained in a preliminary study conducted in Britain in a group of patients of whom most were psychotic, and daily doses of 2 or 3 mg. appeared to be effective in relieving anxiety and agitation in a considerable proportion of these cases (Gillman and Sutherland, 1961). In reviewing the human and animal pharmacology of fluphenazine, Heseltine (1961) commented on its differences from earlier drugs like chlorpromazine and triflupromazine. The increased potency of the new drug, which in many pharmacodynamic properties may be about 40 times as potent as chlorpromazine, is associated with a rapid and prolonged action, relatively little sedative activity and little or no increase in autonomic and haemodynamic effects. A trial was undertaken to investigate the effectiveness of fluphenazine in the treatment of schizophrenic patients.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 109 , Issue 460 , May 1963 , pp. 428 - 432
Copyright
Copyright © Royal College of Psychiatrists, 1963

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baker, A. A., and Thorpe, J. G., J. Ment. Sci., 1956, 102, 838.CrossRefGoogle Scholar
Darling, H. F., Dis. Nerv. Syst., 1959, 20, 167.Google Scholar
Darling, H. F. Hess, G. H., Capistrans, A. C., and Hoermann, M. G., ibid., 1960, 21, 409.Google Scholar
Gillman, S. W., and Sutherland, E. L., in: Fluphenazine in Anxiety and Tension (ed.: Heseltine, W. W.), 1961. Liverpool: Charles Birchall.Google Scholar
Hamilton, M., Smith, A. L. G., Lapidus, H. E., and Cadogan, E. P., J. Ment. Sci., 1960, 106, 40.CrossRefGoogle Scholar
Heseltine, W. W. (ed.), in: Fluphenazine in Anxiety and Tension, 1961. Liverpool: Charles Birchall.Google Scholar
Holt, J. P., and Wright, E. R., Amer. J. Psychiat., 1960, 117, 157.CrossRefGoogle Scholar
Niswander, G. D., and Karacan, I., Dis. Nerv. Syst., 1959, 20, 403.Google Scholar
Taylor, I. J., Amer. J. Psychiat., 1959, 116, 457.CrossRefGoogle Scholar
Taylor, I. J. Dis. Nerv. Syst., 1960, 21, 169.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.